About the Company
Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
44
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DCTH News
Delcath Systems gets grant for optimizing chemotherapeutic agent filtration media pair for cancer treatment
Discover Delcath Systems Inc's innovative method for selecting cytotoxic agents for organ-specific therapy. Learn how their patented process involves filtering blood to remove agents, optimizing ...
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call Transcript
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call Transcript March 26, 2024 Delcath Systems, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ...
Delcath Systems, Inc. (DCTH)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic ...
Delcath Systems Inc DCTH
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Delcath Systems Inc (DCTH) Q4 2023 Earnings Call Transcript
Good day, and welcome to the Delcath Systems Reports Fourth Quarter and Fiscal Year 2023 Financial Results Conference Call. All participants are in a listen-only mode. [Operator Instructions].
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers ...
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call Transcript
Delcath Systems, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Delcath Systems ...
Loading the latest forecasts...